Portfolio News
Sofinnova Industrial Biotech
Biotalys announces successful €54.6 million Initial Public Offering
Biotalys today announces the results of its initial public offering of new shares launched on 23 June 2021 (the "Offering") and the approval of admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol "BTLS" with trading set to commence on 2 July 2021.
Related Strategy
Industrial BiotechRelated Company
BiotalysGhent, BELGIUM – 01 July 2021 – Biotalys NV (“Biotalys” or the “Company”) an Agricultural Technology (AgTech) company focused on addressing food protection challenges with protein-based biocontrol solutions for a more sustainable and safer food supply, today announces the results of its initial public offering of new shares launched on 23 June 2021 (the "Offering") and the approval of admission of all of its shares to trading on the regulated market of Euronext Brussels under the symbol "BTLS" with trading set to commence on 2 July 2021.
The final offer price for the Offering has been set at €7.50 per share, giving the Company an initial market capitalisation of approximately €225.2 million, or approximately €232.3 million, assuming the exercise in full of the Over-allotment Option (defined below). Gross proceeds for the Company from the Offering will amount to approximately €47.5 million, or approximately €54.6 million, assuming the exercise in full of the Over-allotment Option.
The orderbook included support from high-quality long-term institutional investors across Europe and retail investors in Belgium.
Patrice Sellès, Chief Executive Officer of Biotalys, commented: "Today marks a significant milestone for Biotalys and a strong demonstration of confidence and support in our mission to shape the future of sustainable and safe food supply. We have been delighted by the overwhelming support of new investors from across the globe as well as the enduring support of existing investors. This is an exciting time for us and we look forward to realizing the potential of our AGROBODY Foundry™ platform to provide innovative solutions that can transform the way we produce food, from farm to fork."
Related News
NodThera’s oral NLRP3 inhibitor NT-0796 enhances and sustains weight loss in combination with GLP-1
The Phase 3 ABTECT trials in patients with moderately to severely active Ulcerative Colitis
Rasmus Holm-Jorgensen appointed CFO at AAVantgarde
Mainstay Medical announces exclusive coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
Purespring Therapeutics granted European Medicines Agency (EMA) orphan drug designation for PS-002 for the treatment of patients with primary IgA nephropathy (IgAN)